We recently reported that a SART3 tumor-rejection antigen possessing tumor epitopes is capable of inducing HLA class I-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients. We studied the expression of the SART3 protein in mrtsculo.rkeleta/ tumors to find a molecule for potential use in tumor-specific immunotherapy. The SART3 was detected at protein levels in 10004 of the osteosarcoma cell lines (n = 70), in 50% of the musculuslieletal tumor tissue specimens ( n = 37). and at notable levels in 67% of osteosarcoma tissues ( n = 9) and malignant fibrous histiocytosis tissues ( n = 9), respectively. SART3-derived peptides at positions 109-1 18 and 315-313 induced HLA-A?4-restricted tumor-specific cytoxic T lymphocytes from peripheral blood mononuclear cells of patients with osteosarconia or m d i g m n t fibrous histiocytosis. These peptide-induced cytotoxic T lymphocytes recognized HLA-A14+ SART3+ osteosarcoma cells but not H L A -A X or SART3-cells. These results suggest that the SART3 protein and its derived peptides could be molecules appropriate for use in specific immunotherapies for approximately 60% of HLA-A74-patients with osteosarcoma or malignant fibrous histiocytosis. 0 300 1 Orthopaedic Research Society. Published by

No abstract

Summary: We report 4 cases of patellar fracture with skin injury over the patella which were treated operatively immediately after onset with a new reduction technique using Ilizarov pins . This technique made it possible to perform early operative treatment even in the cases with skin injury over the patella which prevents conventional surgical approach.

No abstract

No abstract